DK1047701T3 - Antioxidanter målrettet mod mitokondrier - Google Patents

Antioxidanter målrettet mod mitokondrier

Info

Publication number
DK1047701T3
DK1047701T3 DK98961702T DK98961702T DK1047701T3 DK 1047701 T3 DK1047701 T3 DK 1047701T3 DK 98961702 T DK98961702 T DK 98961702T DK 98961702 T DK98961702 T DK 98961702T DK 1047701 T3 DK1047701 T3 DK 1047701T3
Authority
DK
Denmark
Prior art keywords
compounds
antioxidant
compound
mitochondria
cation
Prior art date
Application number
DK98961702T
Other languages
Danish (da)
English (en)
Inventor
Michael Patrick Murphy
Robin A J Smith
Original Assignee
Antipodean Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antipodean Biotechnology Ltd filed Critical Antipodean Biotechnology Ltd
Application granted granted Critical
Publication of DK1047701T3 publication Critical patent/DK1047701T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/54Quaternary phosphonium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09BORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00Dyes not provided for by a single group of this subclass
    • C09B69/001Dyes containing an onium group attached to the dye skeleton via a bridge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
DK98961702T 1997-11-25 1998-11-25 Antioxidanter målrettet mod mitokondrier DK1047701T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ32925597 1997-11-25
PCT/NZ1998/000173 WO1999026954A1 (en) 1997-11-25 1998-11-25 Mitochondrially targeted antioxidants

Publications (1)

Publication Number Publication Date
DK1047701T3 true DK1047701T3 (da) 2005-08-15

Family

ID=19926531

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98961702T DK1047701T3 (da) 1997-11-25 1998-11-25 Antioxidanter målrettet mod mitokondrier

Country Status (12)

Country Link
EP (1) EP1047701B1 (de)
JP (1) JP4590523B2 (de)
CN (1) CN1318434C (de)
AT (1) ATE296305T1 (de)
AU (2) AU1696499A (de)
CA (1) CA2311318C (de)
DE (1) DE69830338T2 (de)
DK (1) DK1047701T3 (de)
ES (1) ES2244104T3 (de)
NZ (1) NZ505352A (de)
PT (1) PT1047701E (de)
WO (2) WO1999026954A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2474399A (en) * 1998-01-26 1999-08-09 Mitokor Mitochondria protecting agents for treating mitochondria associated diseases
CA2354743A1 (en) * 2001-08-07 2003-02-07 University Of Otago Mitochondrially targeted antioxidants
US6984636B2 (en) 2002-08-12 2006-01-10 Medical Research Council Mitochondrially targeted antioxidants
CA2536546C (en) * 2003-08-22 2012-10-02 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US7888334B2 (en) 2003-08-22 2011-02-15 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US7888335B2 (en) 2003-08-22 2011-02-15 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
NZ528966A (en) * 2003-10-17 2006-11-30 Otago Innovation Ltd Peptide nucleic acid conjugates and uses thereof
BRPI0509757A (pt) * 2004-04-09 2007-10-16 Valorisation Rech Soc En Comma derivados de sais de fosfÈnio e seus usos como auxiliares de controle da solubilidade
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
US9045505B2 (en) 2006-09-28 2015-06-02 University Of Otago Nitric oxide donors
WO2008048134A1 (fr) * 2006-10-20 2008-04-24 Limited Liability Company 'mitotechnology' Compositions pharmaceutiques pour la prévention et le traitement de pathologies oculaires
WO2008048135A1 (fr) 2006-10-20 2008-04-24 Limited Liability Company 'mitotechnology' Composition destinée à la régénération, la stimulation de la croissance et l'adaptation de plantes à tous types de facteurs de stress
WO2008094062A1 (fr) 2007-01-29 2008-08-07 Limited Liability Company 'mitotechnology' Compositions pharmaceutiques servant à la prévention et au traitement de maladies oncologiques
WO2008094061A1 (fr) * 2007-01-29 2008-08-07 Limited Liability Company 'mitotechnology' Compositions pharmaceutiques et cosmétiques servant à accélérer le processus de cicatrisation de plaies et autres lésions superficielles
EA201000142A1 (ru) 2007-04-11 2010-04-30 Общество С Ограниченной Ответственностью "Митотехнология" Композиция, замедляющая старение и увеличивающая продолжительность жизни организма, и ее применение
US8518915B2 (en) 2007-06-29 2013-08-27 Mitotech Sa Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases
KR20160121610A (ko) 2008-04-01 2016-10-19 안티포딘 파마슈티칼스, 인코포레이티드 피부 관리를 위한 조성물 및 방법
WO2010056145A1 (ru) 2008-11-12 2010-05-20 Общество С Ограниченной Ответственностью "Митотехнология" Способ умеренного повышения протонной проводимости биологических мембран при помощи митохондриально- адресованных делокализованных катионов
UA104320C2 (ru) 2009-06-10 2014-01-27 Общество С Ограниченной Ответственностью "Мимотех" Фармацевтическая композиция на основе митохондриально-адресованного антиоксиданта для применения в медицинской и ветеринарной офтальмологии
CA2789846C (en) 2009-11-13 2020-02-25 Obschestvo S Ogranichennoi Otvetstvennostyu "Mitotekh" Pharmaceutical substances on the basis of mitochondria-addressed antioxidants
AU2012261854B2 (en) 2011-06-03 2017-11-16 Mitotech Sa Oral formulations of mitochondrially-targeted antioxidants and their preparation and use
EP3030267A2 (de) * 2013-04-11 2016-06-15 Mitotech SA Mitochondrial angezielte timochinone und toluchinone
CN105939601B (zh) * 2014-01-30 2020-03-10 豪夫迈·罗氏有限公司 在室温稳定全血
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
CN105833289B (zh) * 2016-05-30 2019-04-09 上海交通大学 一种线粒体靶向的纳米药物递送系统及其制备方法与应用
WO2018193114A1 (en) 2017-04-20 2018-10-25 Novintum Biotechnology Gmbh Triphenylphosphonium-tethered tetracycyclines for use in treating cancer
WO2018193117A1 (en) 2017-04-20 2018-10-25 Novintum Biotechnology Gmbh Azithromycin derivatives containing a phosphonium ion as anticancer agents
CA3060892A1 (en) 2017-04-20 2018-10-25 Rising Tide Foundation Azithromycin derivatives containing a phosphonium ion as anticancer agents
WO2018193113A1 (en) 2017-04-20 2018-10-25 Novintum Biotechnology Gmbh Phosphonium-ion tethered tetracycline drugs for treatment of cancer
EP3612177A4 (de) 2017-04-21 2021-01-13 Lunella Biotech, Inc. Targeting von hypoxischen krebsstammzellen (cscs) mit doxycyclin: implikationen zur verbesserung der anti-angiogenesetherapie
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
CA3063450A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
KR20200010343A (ko) 2017-05-19 2020-01-30 루넬라 바이오테크 인코포레이티드 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제
US20210246144A1 (en) 2017-06-26 2021-08-12 Mitotech S.A. A set of mitochondria-targeted compounds
EP3644988B1 (de) 2017-06-26 2023-02-22 Lunella Biotech, Inc. Mitoketoszine: auf mitochondrien basierende therapeutika gegen den ketonmetabolismus in krebszellen
CN109293698B (zh) * 2018-10-15 2021-02-02 山西大学 一种基于苯并噻唑的线粒体pH荧光探针及其制备方法
CN110016048B (zh) * 2019-04-26 2020-06-30 山东大学 线粒体靶向ir780碘化物的衍生物及制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3532667A (en) * 1967-05-31 1970-10-06 Du Pont Polyamides stabilized with phosphonium halides
EP0535283A1 (de) * 1991-10-02 1993-04-07 Merrell Dow Pharmaceuticals Inc. Tocopherol Analoge mit kardioprotektiver Wirkung
CA2354743A1 (en) * 2001-08-07 2003-02-07 University Of Otago Mitochondrially targeted antioxidants

Also Published As

Publication number Publication date
NZ505352A (en) 2002-12-20
CN1282334A (zh) 2001-01-31
AU763179B2 (en) 2003-07-17
AU1696599A (en) 1999-06-15
CA2311318C (en) 2011-11-01
CA2311318A1 (en) 1999-06-03
DE69830338D1 (de) 2005-06-30
EP1047701B1 (de) 2005-05-25
AU1696499A (en) 1999-06-15
WO1999026954A1 (en) 1999-06-03
ATE296305T1 (de) 2005-06-15
DE69830338T2 (de) 2006-02-02
ES2244104T3 (es) 2005-12-01
EP1047701A1 (de) 2000-11-02
EP1047701A4 (de) 2002-03-27
JP4590523B2 (ja) 2010-12-01
WO1999026582A2 (en) 1999-06-03
PT1047701E (pt) 2005-10-31
CN1318434C (zh) 2007-05-30
JP2001524483A (ja) 2001-12-04

Similar Documents

Publication Publication Date Title
DK1047701T3 (da) Antioxidanter målrettet mod mitokondrier
BR9905977A (pt) Moduladores de ccr5
HUP0002454A2 (hu) D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények
CO4940450A1 (es) Formulaciones farmaceuticas que contienen voriconazol
LU91145I9 (de)
DK1033981T3 (da) Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet
BRPI9917007B8 (pt) azabicicloalcanos como moduladores de ccr5, composição farmacêutica contendo os mesmos, bem como seu uso
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
AU7026794A (en) Phosphonooxymethyl ethers of taxane derivatives
ES2171533T3 (es) Composiciones que contienen nebivolol micronizado.
FI962952A (fi) Delta 12,13-iso-taksolianalogit, niiden antineoplastinen käyttö ja niitä sisältävät farmaseuttiset koostumukset
ES2108772T3 (es) Derivados de aminofosfonato substituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ATE331037T1 (de) Isoliertes frpb nukleinsäuremolekül und entsprechende impfstoff
FR2757857B1 (fr) Diselenures et selenosulfures aromatiques, leur preparation et leurs utilisations, notamment therapeutiques
PL346019A1 (en) Nimesulide containing topical pharmaceutical compositions
FI944535A (fi) Rapamysiinikoostumuksia oraalisesti annettaviksi
DE69715173D1 (en) Bisarylcyclobutenderivate als cyclooxygenasehemmer
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
ES2192018T3 (es) Composicion farmaceutica que contiene estimuladores de interferon-gamma.
SE9403137D0 (sv) Derivatives of carbohydrates and compositions containing them
ES2161913T3 (es) Complejos cationicos trinucleares de platino que tienen una actividad antitumoral y composiciones farmaceuticas que los contienen.
SE8602060L (sv) Farmaceutiska kompositioner som innehaller reducerad glutation
ATE434615T1 (de) Farnesyltransferase hemmende benzoheterocyclische derivate
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
TR199800340T1 (xx) �n-ila� 6-N-(L-ALA-L-ALA)-trovafloksasin polimorflar�.